Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, ...

The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis ...

The transaction agreement unreasonably limits competing transactions for Regulus by imposing a significant penalty if Regulus accepts a competing bid. We are investigating the conduct of the Regulus ...